SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number 000-09428
NOTIFICATION OF LATE FILING
(Check One): [X] Form 10-K [_] Form 11-K [_] Form 20-F [_] Form 10-Q
[_] Form N-SAR
For Period Ended: March 31, 2001
--------------------------------------------------------------
[_] Transition Report on Form 10-K [_] Transition Report on Form 10-Q
[_] Transition Report on Form 20-F [_] Transition Report on Form N-SAR
[_] Transition Report on Form 11-K
For the Transition Period Ended: _______________________________________________
Read attached instruction sheet before preparing form. Please print or
type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify item(s) to which the notification relates: ____________________________
________________________________________________________________________________
1
Part I. Registrant Information
Full name of registrant SpectruMedix Corporation
--------------------------------------------------------
Former name if applicable
________________________________________________________________________________
Address of principal executive office (Street and number)
2124 Old Gatesburg Road
--------------------------------------------------------------------------------
City, State and Zip Code State College, Pennsylvania 16803
------------------------------------------------------
Part II. Rule 12b-25(b) and (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check appropriate box.)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before 15th calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will
be filed on or before the fifth calendar day following the prescribed due
date; and
[_] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
Part III. Narrative
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-
Q, N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed).
The Registrant's Annual Report on Form 10-K could not be filed within the
proscribed time period because management was focused on certain business
matters and management was unable to complete its review of the Registrant's
financial statements.
Part IV. Other Information
(1) Name and telephone number of person to contact in regard to this
notification.
Karl Fazler (814) 867-8600
--------------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Sections 13 and 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[X] Yes [_] No
2
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[X] Yes [_] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
For the year ended March 31, 2001, the Registrant will report revenues of
$3,783,057 as compared to revenues of $1,193,405 for the year ended March 31,
2000. The revenues for fiscal year 2001 included over $1,900,000 of sublicense
and consulting fees generated from agreements entered into in July 1999 compared
to approximately $870,000 in 2000. Also, the Registrants sales for the 2001
fiscal year included the sale of seven of the Registrant's principal products
compared to one in 2000.
SpectruMedix Corporation
--------------------------------------------------------------------------------
(Name of registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: July 2, 2001 By: /s/ Joseph K. Adlerstein
------------------- --------------------------------------------
Name: Joseph K. Adlerstein
Title: President and Chief Executive Officer
3